
Tenant Spotlight
How Cyclarity Therapeutics is Taking On the World’s Leading Killer
You think you don’t know someone with atherosclerosis, but it’s likely you actually do. Atherosclerosis is the build-up of oxidized cholesterol in arteries, an underlying factor in an astonishing 50% of deaths in Western society. An indicator of dementia, Alzheimer’s, heart disease, lung disease, and more, it’s one of the first detectable signs of aging.
As co-founder and CEO of scientific affairs at Cyclarity Therapeutics, Matthew “Oki” O’Connor directs a team developing a drug to neutralize this killer.
Oki’s potentially life-saving breakthrough came in the form of the least scientific experiment imaginable. In early 2018, he worked in Mountain View at the SENS Research Foundation, which is dedicated to finding cures for aging-related disease. It was on a quiet Friday night when everyone in the lab was either out sick, traveling, or home, that he decided to test out their first prototype.